Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 7
Submit an article Journal homepage
169
Views
58
CrossRef citations to date
0
Altmetric
Original

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206

Kristie A. Blum Division of Hematology – Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OHCorrespondence[email protected]
,
Jeffrey L. Johnson CALGB Statistical Center, Duke University Medical Center, Durham, NC
,
Donna Niedzwiecki CALGB Statistical Center, Duke University Medical Center, Durham, NC
,
George P. Canellos Division of Hematology – Oncology, Department of Internal Medicine, Dana Farber Cancer Center, Boston, MA
,
Bruce D. Cheson Division of Hematology – Oncology, Department of Internal Medicine, Georgetown University Hospital, Washington, DC
&
Nancy L. Bartlett Division of Hematology – Oncology, Department of Internal Medicine, Washington University, St. Louis, MO
Pages 1313-1319 | Received 03 Apr 2007, Accepted 20 Apr 2007, Published online: 01 Jul 2009

Citations (58)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Shinichi Makita, Dai Maruyama & Kensei Tobinai. (2020) Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. OncoTargets and Therapy 13, pages 5993-6009.
Read now
Theodoros Karantanos, Ioannis Politikos & Vassiliki A Boussiotis. (2017) Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood and Lymphatic Cancer: Targets and Therapy 7, pages 37-52.
Read now
Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, Angelo Michele Carella, Umberto Vitolo, Eleonora Russo, Angelagiovanna Congiu, Manuel Gotti, Stefania Massidda, Barbara Botto, Giorgia Annechini, Michele Spina, Alessandro Re, Vittorio Ruggero Zilioli, Francesco Merli, Flavia Salvi, Caterina Stelitano, Maurizio Bonfichi, Marcello Rodari, Roberta Murru, Massimo Magagnoli, Antonella Anastasia, Rita Mazza, Laura Giordano & Armando Santoro. (2016) B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). Leukemia & Lymphoma 57:10, pages 2375-2381.
Read now
Vijayveer Bonthapally, Hongbo Yang, Rajeev Ayyagari, Ruo-Ding Tan, Sean Cai, Eric Wu, Ashish Gautam, Andy Chi & Dirk Huebner. (2015) Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. Current Medical Research and Opinion 31:7, pages 1377-1389.
Read now
Vijayveer Bonthapally, Eric Wu, Alexander Macalalad, Hongbo Yang, Oluwatoyin Shonukan, Yi Liu, Andy Chi & Dirk Huebner. (2015) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Current Medical Research and Opinion 31:5, pages 993-1001.
Read now
Heiner Adams, Ellen C Obermann, Stephan Dirnhofer & Alexandar Tzankov. (2011) Targetable molecular pathways in classical Hodgkin's lymphoma. Expert Opinion on Investigational Drugs 20:2, pages 141-151.
Read now
David Sibon & Pauline Brice. (2009) Optimal treatment for relapsing patients with Hodgkin lymphoma. Expert Review of Hematology 2:3, pages 285-295.
Read now
Tanya M. Wildes & Nancy L. Bartlett. (2009) Drug development for recurrent and refractory classical Hodgkin lymphoma. Leukemia & Lymphoma 50:4, pages 529-540.
Read now
Jan Sterz, Ivana von Metzler, Jens-Claus Hahne, Britta Lamottke, Jessica Rademacher, Ulrike Heider, Evangelos Terpos & Orhan Sezer. (2008) The potential of proteasome inhibitors in cancer therapy. Expert Opinion on Investigational Drugs 17:6, pages 879-895.
Read now
Antonio Russo, Maria E Fratto, Viviana Bazan, Valentina Schiró, Valentina Agnese, Giuseppe Cicero, Bruno Vincenzi, Giuseppe Tonini & Daniele Santini. (2007) Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. Expert Opinion on Therapeutic Targets 11:12, pages 1571-1586.
Read now

Articles from other publishers (48)

Fabrice Jardin. (2022) NFkB Pathway and Hodgkin Lymphoma. Biomedicines 10:9, pages 2153.
Crossref
Frank C. PasseroJrJr, Dashnamoorthy Ravi, J. Tyson McDonald, Afshin Beheshti, Kevin A. David & Andrew M. Evens. (2019) Combinatorial ixazomib and belinostat therapy induces NFE2L2‐dependent apoptosis in Hodgkin and T‐cell lymphoma. British Journal of Haematology 188:2, pages 295-308.
Crossref
K D Wurster, F Hummel, J Richter, M Giefing, S Hartmann, M-L Hansmann, S Kreher, K Köchert, D Krappmann, W Klapper, M Hummel, S-S Wenzel, G Lenz, M Janz, B Dörken, R Siebert & S Mathas. (2016) Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Leukemia 31:3, pages 602-613.
Crossref
Tatjana Maria Swerev, Thomas Wirth & Alexey Ushmorov. (2017) Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors. International Journal of Oncology 50:2, pages 555-566.
Crossref
Dashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, Frank Passero, Jaya Sharma, Michael Coyle, Athena Kritharis, Irawati Kandela, Lynn Hlatky, Michail V. Sitkovsky, Andrew Mazar, Ronald B. Gartenhaus & Andrew M. Evens. (2016) Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. Cancer Research 76:11, pages 3319-3331.
Crossref
Ling Peng, Xianghua Ye, Yun Zhou, Junyan Zhang & Qiong Zhao. (2015) Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Supportive Care in Cancer 23:9, pages 2813-2824.
Crossref
Antonino Carbone & Anas YounesConnie Lee Batlevi & Anas Younes. 2015. Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2). Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2) 36 55 .
Christian Marinaccio, Beatrice Nico, Eugenio Maiorano, Giorgina Specchia & Domenico Ribatti. (2014) Insights in Hodgkin Lymphoma angiogenesis. Leukemia Research 38:8, pages 857-861.
Crossref
Mariano Provencio, Antonio Sánchez & Margarita Sánchez-Beato. (2014) New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treatment Reviews 40:3, pages 457-464.
Crossref
Catherine Diefenbach & Ranjana Advani. (2014) Customized Targeted Therapy in Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 105-122.
Crossref
Nida Iqbal, Lalit Kumar & Naveed Iqbal. (2014) Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant. ISRN Oncology 2014, pages 1-7.
Crossref
Connie Lee Batlevi & Anas Younes. (2013) Novel therapy for Hodgkin lymphoma. Hematology 2013:1, pages 394-399.
Crossref
Catherine Diefenbach & Christian Steidl. (2013) New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments. Clinical Cancer Research 19:11, pages 2797-2803.
Crossref
Shundong Cang, Nikhil Mukhi, Kemeng Wang & Delong Liu. (2012) Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology & Oncology 5:1.
Crossref
Marta Bruno Ventre & Andrés JM Ferreri. (2012) Novel agents for lymphomas: the hopeful puzzle. International Journal of Hematologic Oncology 1:1, pages 11-14.
Crossref
H Mizuno, T Nakayama, Y Miyata, S Saito, S Nishiwaki, N Nakao, K Takeshita & T Naoe. (2012) Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 26:10, pages 2269-2276.
Crossref
Seon-Yong Yeom, Sook-Ja Lee, Won Seog Kim & Chaehwa Park. (2012) Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells. Leukemia Research 36:9, pages 1172-1178.
Crossref
William Townsend & David Linch. (2012) Hodgkin's lymphoma in adults. The Lancet 380:9844, pages 836-847.
Crossref
Jieun Uhm & John Kuruvilla. (2012) Treatment of newly diagnosed advanced stage Hodgkin lymphoma. Blood Reviews 26:4, pages 167-174.
Crossref
Radhakrishnan Ramchandren. (2012) Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma. The Oncologist 17:3, pages 367-376.
Crossref
Ádám Jóna, Árpád Illés & Anas Younes. 2012. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics 181 202 .
Orla Maguire, Christine Collins, Kieran O'Loughlin, Jeffrey Miecznikowski & Hans Minderman. (2011) Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot. Cytometry Part A 79A:6, pages 461-469.
Crossref
Christian SteidlJoseph M. ConnorsRandy D. Gascoyne. (2011) Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. Journal of Clinical Oncology 29:14, pages 1812-1826.
Crossref
Alyson J. Smith, Haiming Dai, Cristina Correia, Rie Takahashi, Sun-Hee Lee, Ingo Schmitz & Scott H. Kaufmann. (2011) Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells. Journal of Biological Chemistry 286:20, pages 17682-17692.
Crossref
Michael Crump. 2011. Advances in Malignant Hematology. Advances in Malignant Hematology 296 314 .
Anas Younes. (2010) Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nature Reviews Clinical Oncology 8:2, pages 85-96.
Crossref
S. E. Richardson & C. McNamara. (2011) The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future. Advances in Hematology 2011, pages 1-17.
Crossref
Anas Younes & Andreas Engert. 2011. Hodgkin Lymphoma. Hodgkin Lymphoma 283 294 .
Kristie A. Blum. (2010) Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma. Hematology 2010:1, pages 93-100.
Crossref
Patrick B Johnston, RuiRong Yuan, Franco Cavalli & Thomas E Witzig. (2010) Targeted therapy in lymphoma. Journal of Hematology & Oncology 3:1.
Crossref
John W. Sweetenham. (2010) Novel therapies for Hodgkin lymphoma. Therapeutic Advances in Hematology 1:1, pages 23-29.
Crossref
Adam Jona & Anas Younes. (2010) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Reviews 24:6, pages 233-238.
Crossref
Patrick B. Johnston, David J. Inwards, Joseph P. Colgan, Betsy R. Laplant, Brian F. Kabat, Thomas M. Habermann, Ivana N. Micallef, Luis F. Porrata, Stephen M. Ansell, Craig B. Reeder, Vivek Roy & Thomas E. Witzig. (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology 85:5, pages 320-324.
Crossref
Jennifer Freed & Kara M. Kelly. (2010) Current Approaches to the Management of Pediatric Hodgkin Lymphoma. Pediatric Drugs 12:2, pages 85-98.
Crossref
A M Vahdat, K S Reiners, V L Simhadri, D A Eichenauer, B Böll, A Chalaris, V R Simhadri, K Wiegmann, H-W Krell, S Rose-John, A Engert, E P von Strandmann & H P Hansen. (2009) TNF-α-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia 24:1, pages 51-57.
Crossref
Aaron WeissMichelle NeierRichard A Drachtman. (2009) Pediatric Hodgkin lymphoma: past, present and future. Pediatric Health 3:6, pages 593-606.
Crossref
John Gerecitano. (2009) The future of small molecule inhibitors in lymphoma. Current Oncology Reports 11:5, pages 378-385.
Crossref
Bruce D Cheson. (2009) Novel therapies for peripheral T-cell non-Hodgkinʼs lymphomas. Current Opinion in Hematology 16:4, pages 299-305.
Crossref
Malcolm A. Smith. (2009) Update on developmental therapeutics for acute lymphoblastic leukemia. Current Hematologic Malignancy Reports 4:3, pages 175-182.
Crossref
Savita Bhalla, Sriram Balasubramanian, Kevin David, Mint Sirisawad, Joseph Buggy, Lauren Mauro, Sheila Prachand, Richard Miller, Leo I. Gordon & Andrew M. Evens. (2009) PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. Clinical Cancer Research 15:10, pages 3354-3365.
Crossref
Jason H. Mendler & Jonathan W. Friedberg. (2009) Salvage Therapy in Hodgkin’s Lymphoma. The Oncologist 14:4, pages 425-432.
Crossref
Michael B. Armstrong. (2009) Proteasome Inhibition: Thinking outside the Box. Clinical Medicine. Therapeutics 1, pages CMT.S3072.
Crossref
Anas Younes. (2009) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology 2009:1, pages 507-519.
Crossref
J.H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R.M. Rossi, S.H. Bernstein, C.T. Jordan, J. Liesveld, R.I. Fisher & J.W. Friedberg. (2008) Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology 19:10, pages 1759-1764.
Crossref
Nancy L Bartlett. (2008) Modern treatment of Hodgkin lymphoma. Current Opinion in Hematology 15:4, pages 408-414.
Crossref
Michael Crump. (2008) Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant. Hematology 2008:1, pages 326-333.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:1, pages 46-53.
Crossref
Kevin A. David, Lauren Mauro & Andrew M. Evens. (2008) Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic Options. Current Treatment Options in Oncology 8:5, pages 352-374.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.